Ocugen Inks Exclusive Rights Deal for OCU400 in MENA

By Tamara Parker • Monday, July 13 10:53 • Permanent Link

Ocugen said July 13, 2026, it signed a binding term sheet with Roots Pharmaceutical and its strategic partner Al-Dhow International Holding for exclusive rights to OCU400 in the Middle East and North Africa.

Under the proposed license agreement, Ocugen expects to receive up to $4 million in upfront license fees and near-term development milestone payments. The company also could collect up to $255 million in sales milestones, plus a 22% royalty on net sales generated by its partner.

Ocugen will also manufacture commercial supply of OCU400 under a related supply agreement.

The deal adds a new regional commercialization path for OCU400, Ocugen’s modifier gene therapy for retinitis pigmentosa, a disease the company said has notable prevalence across the MENA region.

Ocugen said the definitive agreement is expected within 90 days.

The company also said OCU400 remains in Phase 3 LIMELIGHT, with topline data expected in the first quarter of 2027 and a biologics license application submission to follow. Today the company's shares have moved -2.72% to a price of $1.43. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.